news & events
portfolio news
20.01.15
AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury
22.12.14
TiGenix submits its pivotal US trial design for Cx601 to the FDA for Special Protocol Assessment
10.12.14
TiGenix starts Phase I trial of Cx611 in severe sepsis
13.11.14
AM-Pharma presents preclinical data on mode-of-action for recAP in Acute Kidney Injury at ASN meeting
12.11.14
TiGenix completes patient recruitment for the European Phase III trial of Cx601 ahead of schedule
23.10.14
MedLumics Introduces NITID Skin Imaging System at EADV
07.10.14
CVRx® Announces First Successful Barostim Heart Failure Commercial Implants in Europe
30.09.14
CVRx® Receives CE Mark Approval of the Barostim neo System™ for the Treatment of Heart Failure
22.09.14
CVRx® Secures $15 Million Growth Capital Facility from Silicon Valley Bank
16.09.14
AM-Pharma closes €12.2m financing round
